This content is in French.
A New Era for Bladder Cancer Detection?
21 novembre 2026

Bladder cancer diagnosis and surveillance rely heavily on cystoscopy and urine cytology. These approaches have limitations. Cystoscopy is invasive and requires repeated examinations, while cytology has relatively low sensitivity, particularly for low-grade tumours. More accurate urine-based biomarkers could improve early detection, disease monitoring and treatment selection.
In a study published online in October 2026 in Nature Medicine, Kevin J. Liu and colleagues investigated whether cell-free RNA (cfRNA) in urine could provide a reliable molecular signature of bladder cancer. Unlike DNA-based approaches, cfRNA reflects gene expression and may reveal tumour characteristics, immune activity and treatment response.
Sign in to read the rest
Reserved for healthcare professionals, free registration.


